Retina Implant AG Clinical Trial Results Presented at the 2013 American Academy of Ophthalmology Annual Meeting

-- Dr. Katarina Stingl Shares Work on CE Marked Subretinal Implant Technology During the Young Ophthalmologists Session

NEW ORLEANS, Nov. 18, 2013 /PRNewswire/ -- Retina Implant AG, the leading developer of subretinal implants for patients blinded by retinitis pigmentosa (RP), today announced that Dr. Katarina Stingl, clinical scientist from the Centre for Ophthalmology, University of Tuebingen, Germany presented results from the Company sponsored clinical trial that led to CE mark of the Alpha IMS at the American Academy of Ophthalmology (AAO) annual meeting. The presentation took place on Sunday, November 17 from 3:00-4:30 p.m. at the Ernest N. Morial Convention Center in New Orleans, La.

(Logo: http://photos.prnewswire.com/prnh/20130201/NE51162LOGO )

Dr. Stingl's presentation in the course, "2013 Modern Technologies and Techniques for Young Ophthalmologists to Know," covered new techniques, approaches and therapies for treating hereditary retinal degenerations that are in use internationally, but are not yet available in the United States. The key focus of the presentation was clinical trial results of the Alpha IMS subretinal implant, which obtained CE mark to restore useful vision to RP patients in July 2013. The results, also published earlier this year in Proceedings of the Royal Society Biological Science, found that functional vision was restored in the majority of patients implanted with a wireless subretinal microchip. Patients were followed over an observation period of three to nine months and reported benefits such as regaining the ability to read letters and see facial characteristics.

"Being invited to present research to this great group of individuals at this prestigious meeting was a great honor," said Dr. Katarina Stingl, clinical scientist from the Centre for Ophthalmology, University of Tuebingen, Germany. "After years of research we are finally able to provide a path to restore parts of functional vision for people suffering from end-stage retinitis pigmentosa, a degenerative disease that most often leads to blindness. It's been thrilling to be part of this ground breaking research, and it's a privilege to share our learnings with my esteemed peers."

"A lot of progress has been made in the decade since Retina Implant was born. Our success is due, in large part, to outstanding researchers, like Dr. Stingl, who have led our clinical trials," said Walter-G Wrobel, CEO of Retina Implant AG. "Our immediate focus is to expand access to our technology within the European Union as well in other parts of the world, including working with the FDA to approve a trial in the U.S."

The Alpha IMS is a 3x3 mm² wireless subretinal microchip with 1,500 electrodes implanted below the retina, specifically in the macular region. The Alpha IMS provides artificial vision in implanted patients partly by taking over, in part, the function of the photoreceptors within the eye and transmitting the visual image in the form of electrical signals to the bipolar cells.

About Retinitis Pigmentosa
Retinitis pigmentosa (RP) is one of the most common forms of inherited retinal degenerations affecting 1.5 million worldwide. A progressive condition that gets worse over time, RP typically causes severe vision problems in adulthood. Retinal implants represent promise for enabling RP patients to regain functional sight.

About Retina Implant AG
Retina Implant AG is the leading developer of subretinal implants for partially sighted and blind patients. After extensive research with German university hospitals and institutes which began with a large grant from the German Federal Ministry of Research and Education in 1996, Retina Implant AG was founded by Dr. Eberhart Zrenner, professor of Ophthalmology, University of Tuebingen, Germany and his colleagues in 2003 with private investors with the goal of developing the first fully-functioning electronic retinal implant to restore useful vision to the blind. Retina Implant began implanting in human patients in 2005, and started a second multi-center clinical trial in 2010. In July 2013, Retina Implant's wireless subretinal implant technology, Alpha IMS, received CE mark. To learn more, visit http://www.retina-implant.de/.